Nicholas Simon

Nicholas Simon has been a managing director of Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, he was a general partner at MPM Capital, a healthcare venture capital firm. He has more than 30 years of operating and investment experience in the biopharmaceutical industry, including serving as vice president of business and corporate development at Genentech. Simon is currently a member of the board of directors of Gritstone Oncology, Lycera, Nuvelution Pharma and Sientra. He has been a member of the board of directors of numerous private and public life science companies, including Achillion (ACHN), Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals), Barrier Therapeutics (acquired by Stiefel Laboratories), Biovitrum AB (SOBI), Cotherix (acquired by Actelion), InterMune (acquired by Roche), Pearl Therapeutics (acquired by AstraZeneca), Quatrx Pharmaceuticals, Rigel (RIGL), Rinat (acquired by Pfizer) and Sangstat (acquired by Genzyme/Sanofi). Simon is Trustee at the Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco.
He received a BS in microbiology from the University of Maryland and an MBA from Loyola University.